Article
Development of ceftazidime-avibactam resistance driven by conversion of blaKPC-2 to blaKPC-78 during treatment of ST463 carbapenem-resistant Pseudomonas aeruginosa infection.
International journal of antimicrobial agents - 1 Feb 2026
Xu Haotian, Zhang Tingjuan, Cui Xueying, Guo Jingyi, Min Pengpeng, Wu Chengjin, Tang Xinyan, Zhou Longjie, Wang Linfang, Li Xi
Abstract excerpt
OBJECTIVE: The emergence of ceftazidime-avibactam (CZA)-resistant carbapenem-resistant Pseudomonas aeruginosa (CRPA) poses a major clinical challenge in contemporary clinical practice. In this study, we report the first identification of blaKPC-78, which is driven by a mutation from blaKPC-2 in a clinical CRPA strain. METHODS: Six blaKPC-78 CRPA isolates, along with two blaKPC-2 strains from one patient, were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.